BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind ...
The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by Adobe Stock/HealthDay News Preeclampsia can be a life-threatening ...
Laboratory Corporation of America Holdings, Inc., or LabCorp LH, recently launched a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia. The preeclampsia is ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
BURLINGTON, North Carolina -- LabCorp has received emergency use authorization from the Food and Drug Administration for its Pixel at home coronavirus test kit. The COVID-19 At Home Test Kit allows ...
(RTTNews) - Labcorp (LH) announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
A new Labcorp technique for early detection of Alzheimer’s disease for adults ages 50 and older has become available nationwide, the Burlington company announced last week. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback